The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • Gene obtained from curated document aligns with the Allele Registry but not with ClinVar data
  • No CSPEC computed assertion could be determined for this classification!


Variant: NM_001100.4(ACTA1):c.124C>T (p.His42Tyr)

CA345151235

1452968 (ClinVar)

Gene: ACTA1 (HGNC:58)
Condition: alpha-actinopathy (MONDO:0100084)
Inheritance Mode: Autosomal dominant inheritance
UUID: ac6e8233-e5c6-4ff0-b854-961d3d2c5944
Approved on: 2024-08-27
Published on: 2024-12-12

HGVS expressions

NM_001100.4:c.124C>T
NM_001100.4(ACTA1):c.124C>T (p.His42Tyr)
NC_000001.11:g.229432992G>A
CM000663.2:g.229432992G>A
NC_000001.10:g.229568739G>A
CM000663.1:g.229568739G>A
NC_000001.9:g.227635362G>A
NG_006672.1:g.6105C>T
ENST00000366683.4:c.124C>T
ENST00000684723.1:c.-6-112C>T
ENST00000366683.3:c.124C>T
ENST00000366684.7:c.124C>T
NM_001100.3:c.124C>T
More

Pathogenic

Met criteria codes 7
PS2 PS3 PS4_Moderate PP4_Moderate PP3 PP2 PM2_Supporting
Not Met criteria codes 4
BA1 BS3 BS1 BP4

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Congenital Myopathies Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for ACTA1 Version 2.0.0

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Congenital Myopathies VCEP
The NM_001100.4:c.124C>T variant in ACTA1 is a missense variant predicted to cause substitution of histidine by tyrosine at amino acid 42 (legacy nomenclature: p.His40Tyr). This variant is absent from gnomAD v4.1 (PM2_Supporting). The computational predictor REVEL gives a score of 0.72, which is above the threshold of 0.7, evidence that correlates with impact to ACTA1 function (PP3). ACTA1, in which the variant was identified, is defined by the ClinGen Congenital Myopathies VCEP as a gene that has a low rate of benign missense variation and where pathogenic missense variants are a common mechanism of disease (PP2). In vitro studies demonstrated changes in actin localization and motility (PMID:15226407, 17227580, 27112274). In vivo studies in a mouse model demonstrated impaired function of ACTA1 and limited intrinsic force-generating capacity and maximal tetanic force (PMID:23613869, 23656990)(PS3). This variant has been reported in 4 probands/families with intranuclear rod and/or nemaline myopathies (PS4_Moderate; PMID:10508519, 12921789, 19562689). This variant has occured de novo with confirmed parental relationships in 1 individual and was reported to occur de novo with unconfirmed parental relationships in 1 individual with severe atypical nemaline myopathy with intranuclear nemaline bodies (PS2, PP4_Moderate; PMID:10508519, 19562689). In summary, this variant meets the criteria to be classified as pathogenic for autosomal dominant alpha-actinopathy based on the ACMG/AMP criteria applied, as specified by the ClinGen Congenital Myopathies VCEP: PS2, PS3, PS4_Moderate, PP4_Moderate, PM2_Supporting, PP2, PP3 (Congenital Myopathies VCEP specifications version 2; 08/27/2024.
Met criteria codes
PS2
This variant has occured de novo with confirmed parental relationships in 1 individual and was reported to occur de novo with unconfirmed parental relationships in 1 individual with severe atypical nemaline myopathy with intranuclear nemaline bodies (PS2; PMID:10508519, 19562689).
PS3
In vitro studies demonstrated changes in actin localization and motility (PMID:15226407, 17227580, 27112274). In vivo studies in a mouse model demonstrated impaired function of ACTA1 and limited intrinsic force-generating capacity and maximal tetanic force (PMID:23613869, 23656990)(PS3).
PS4_Moderate
This variant has been reported in 4 probands/families with intranuclear rod and/or nemaline myopathies (PS4_Moderate; PMID:10508519, 12921789, 19562689).
PP4_Moderate
This variant has occured de novo with confirmed parental relationships in 1 individual and was reported to occur de novo with unconfirmed parental relationships in 1 individual with severe atypical nemaline myopathy with intranuclear nemaline bodies (PS2, PP4_Moderate; PMID:10508519, 19562689).
PP3
The computational predictor REVEL gives a score of 0.72, which is above the threshold of 0.7, evidence that correlates with impact to ACTA1 function (PP3).
PP2
ACTA1, in which the variant was identified, is defined by the ClinGen Congenital Myopathies VCEP as a gene that has a low rate of benign missense variation and where pathogenic missense variants are a common mechanism of disease (PP2).
PM2_Supporting
This variant is absent from gnomAD v4.1 (PM2_Supporting).
Not Met criteria codes
BA1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS3
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP4
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
ClinGen Terms of Use.
¤ Powered by BCM's Genboree.